Paraneoplastic acute exudative polymorphous vitelliform maculopathy improved with intravitreal methotrexate
Related Experiment Video
Updated: Dec 7, 2025
Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
Jie Gao1,2, Ketaki Panse1,2, C Stephen Foster1,2,3
1Massachusetts Eye Research and Surgery Institution, United States.
Purpose:
To describe a case of acute exudative polymorphous vitelliform maculopathy (AEPVM) treated with intravitreal methotrexate.
Observations:
A 58-year-old man with a history of metastatic melanoma developed paraneoplastic acute exudative polymorphous vitelliform maculopathy, refractory to oral prednisone, intravitreal bevacizumab and intravitreal preservative-free triamcinolone. Improvement in vision and resolution of subfoveal fluid was later seen after intravitreal methotrexate therapy.
Conclusions And Importance:
AEPVM is a rare and poorly understood retinal disorder that may be idiopathic or may manifest in patients with malignancies. The pathogenic process is thought to be an attack directed against the retinal pigment epithelium (RPE) and photoreceptors. Intravitreal methotrexate may provide benefit when treating AEPVM, especially when trials of steroids and anti-VEGF medications have failed.
